Haploidentical stem cell transplantation-bone marrow vs peripheral blood
- PMID: 29764770
- DOI: 10.1016/j.transci.2018.04.015
Haploidentical stem cell transplantation-bone marrow vs peripheral blood
Abstract
Hematopoietic stem cells may be obtained by collection of bone marrow, mobilization and collection of peripheral blood stem cells or umbilical cord blood. Transplantation of peripheral blood hematopoietic cells has increased due to faster engraftment and practicability in both the related, unrelated or haploidentical setting. We reviewed the question of which stem cell source - bone marrow (BM) or peripheral blood (PBSC) - is the most suitable for individuals undergoing haploidentical stem cell transplantation. BM or PBSC could be safely used as allograft sources for haploidentical transplantation with good outcomes and acceptable rates of GVHD and graft failure. Prospective randomized studies are needed to evaluate the effect of PB vs BM in haploidentical settings.
Keywords: Bone marrow; Haploidentical stem cell transplantation; Peripheral blood; Post transplant cyclophosphamide.
Copyright © 2018. Published by Elsevier Ltd.
Similar articles
-
Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis.Crit Rev Oncol Hematol. 2019 Jan;133:120-128. doi: 10.1016/j.critrevonc.2018.05.017. Epub 2018 Jun 11. Crit Rev Oncol Hematol. 2019. PMID: 30661648
-
Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.Biol Blood Marrow Transplant. 2015 Aug;21(8):1506-14. doi: 10.1016/j.bbmt.2015.04.025. Epub 2015 May 19. Biol Blood Marrow Transplant. 2015. PMID: 26001696
-
Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.Biol Blood Marrow Transplant. 2009 Feb;15(2):266-73. doi: 10.1016/j.bbmt.2008.11.029. Biol Blood Marrow Transplant. 2009. PMID: 19167687 Clinical Trial.
-
Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors.Biol Blood Marrow Transplant. 2015 Sep;21(9):1641-5. doi: 10.1016/j.bbmt.2015.06.006. Epub 2015 Jun 14. Biol Blood Marrow Transplant. 2015. PMID: 26079442
-
Peripheral Blood or Bone Marrow Stem Cells? Practical Considerations in Hematopoietic Stem Cell Transplantation.Transfus Med Rev. 2019 Jan;33(1):43-50. doi: 10.1016/j.tmrv.2018.11.003. Epub 2018 Nov 12. Transfus Med Rev. 2019. PMID: 30528986 Review.
Cited by
-
Aligning the Cord Blood-Bone Marrow Differences and the Post-transplantation Clinical Manifestations by Single-Cell RNA-Seq.Cell Transplant. 2023 Jan-Dec;32:9636897231193067. doi: 10.1177/09636897231193067. Cell Transplant. 2023. PMID: 37650431 Free PMC article.
-
Reduced-toxicity conditioning regimen with low dose post-transplantation cyclophosphamide and low-dose anti-thymocyte globulin as graft-versus-host disease prophylaxis for haploidentical stem cell transplantation in older patients.Ann Hematol. 2024 Aug;103(8):3135-3143. doi: 10.1007/s00277-024-05818-5. Epub 2024 May 29. Ann Hematol. 2024. PMID: 38809457
-
Hematopoietic reconstitution dynamics of mobilized- and bone marrow-derived human hematopoietic stem cells after gene therapy.Nat Commun. 2023 May 27;14(1):3068. doi: 10.1038/s41467-023-38448-y. Nat Commun. 2023. PMID: 37244942 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
